Dacarbazine (DTIC-Dome) — Clinical FAQs

Question 1

What is Dacarbazine FDA-approved to treat?

Accepted Answer

Dacarbazine is FDA-approved for the following oncology indications: 1. Metastatic malignant melanoma 2. Hodgkin lymphoma (second-line and in ABVD regimen).

Question 2

How does Dacarbazine work (mechanism of action)?

Accepted Answer

Dacarbazine is an alkylating triazene prodrug that requires metabolic activation via N-demethylation by hepatic CYP1A2 to generate the active monomethyl triazeno metabolite, MTIC (5-(3-methyltriazen-1-yl)imidazole-4-carboxamide). MTIC spontaneously decomposes to release a methyldiazonium ion that methylates DNA predominantly at the O⁶ and N⁷ positions of guanine, forming DNA adducts that cause cross-links and strand breaks, ultimately inhibiting DNA replication and transcription. Dacarbazine also has minor antimetabolite activity by inhibiting purine synthesis. It is cell-cycle nonspecific, with activity across multiple phases; however, maximal cytotoxicity is observed in the S phase.

Question 3

How is Dacarbazine administered?

Accepted Answer

Dacarbazine is administered Intravenous (IV). Reconstitute vials with sterile water for injection (100 mg in 9.

Question 4

What are the most common side effects of Dacarbazine?

Accepted Answer

The most commonly reported side effects of Dacarbazine (≥10% incidence) include: Nausea and vomiting (severe; occurs in >90% of patients — highly emetogenic, classified HEC), Anorexia, Myelosuppression: leukopenia and thrombocytopenia (nadir at 21–25 days), Flu-like syndrome: fever, malaise, myalgia (occurs 7 days after treatment), Alopecia (mild) and others (8 total). Consult your oncologist for complete prescribing information.

Question 5

Does Dacarbazine have a black box warning?

Accepted Answer

Yes. Dacarbazine carries FDA black box warning(s) regarding: 1. Hematopoietic depression: Dacarbazine causes dose-limiting myelosuppression — leukopenia and thrombocytopenia can be severe and may lead to fatal infections or bleeding. Monitor CBC; therapy should be withheld for significant hematologic toxicity. 2. Hepatotoxicity: Hepatic necrosis due to hepatic vein thrombosis and hepatocellular damage has been reported and can be fatal. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) has occurred, particularly with concurrent use of other hepatotoxic agents. 3. Carcinogenesis and mutagenesis: Dacarbazine is carcinogenic and mutagenic in animals. Secondary malignancies, including acute leukemia, have been reported in patients treated with dacarbazine-containing regimens.

Question 6

Is Dacarbazine safe during pregnancy?

Accepted Answer

Dacarbazine pregnancy safety: Category C — Dacarbazine has been shown to be teratogenic and embryotoxic in animal studies at doses equivalent to human doses. Women of childbearing potential should be advised to avoid pregnancy during therapy. Although FDA Category C, many oncology guidelines treat it as effectively contraindicated in pregnancy due to embryotoxic potential.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Dacarbazine — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms